Header

UZH-Logo

Maintenance Infos

Antigen-specific tolerization approaches in multiple sclerosis


Lutterotti, A; Martin, R (2014). Antigen-specific tolerization approaches in multiple sclerosis. Expert Opinion on Investigational Drugs, 23(1):9-20.

Abstract

Introduction: Inhibition of self-reactive T cells through induction of antigen-specific immune tolerance holds the promise of effective treatment of autoimmune pathology with few side effects and preservation of normal immune functions. In multiple sclerosis (MS) several approaches have been tested already in clinical trials or are currently ongoing with the aim to inhibit myelin-reactive immune responses. Areas covered: This article provides an overview of the recent and ongoing strategies to inhibit specific immune responses in MS, including different applications of myelin peptide-based approaches, T-cell vaccination, DNA vaccination and antigen-coupled cells. Expert opinion: Despite difficulties in translation of antigen-specific therapies in MS, novel approaches have the potential to effectively induce immune tolerance and ameliorate the disease. To improve efficacy of treatments, future trials should include patients in the early phases of the disease, when the autoimmune response is predominant and immune reactivity still focused. The target antigens are not fully defined yet, and robust immunomonitoring assays should developed to provide mechanistic proof of concept in parallel to showing efficacy with respect to inhibiting inflammatory disease activity in the central nervous system (CNS).

Abstract

Introduction: Inhibition of self-reactive T cells through induction of antigen-specific immune tolerance holds the promise of effective treatment of autoimmune pathology with few side effects and preservation of normal immune functions. In multiple sclerosis (MS) several approaches have been tested already in clinical trials or are currently ongoing with the aim to inhibit myelin-reactive immune responses. Areas covered: This article provides an overview of the recent and ongoing strategies to inhibit specific immune responses in MS, including different applications of myelin peptide-based approaches, T-cell vaccination, DNA vaccination and antigen-coupled cells. Expert opinion: Despite difficulties in translation of antigen-specific therapies in MS, novel approaches have the potential to effectively induce immune tolerance and ameliorate the disease. To improve efficacy of treatments, future trials should include patients in the early phases of the disease, when the autoimmune response is predominant and immune reactivity still focused. The target antigens are not fully defined yet, and robust immunomonitoring assays should developed to provide mechanistic proof of concept in parallel to showing efficacy with respect to inhibiting inflammatory disease activity in the central nervous system (CNS).

Statistics

Citations

Dimensions.ai Metrics
19 citations in Web of Science®
19 citations in Scopus®
18 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

69 downloads since deposited on 18 Dec 2013
41 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2014
Deposited On:18 Dec 2013 16:48
Last Modified:14 Feb 2018 20:52
Publisher:Informa Healthcare
ISSN:1354-3784
OA Status:Green
Publisher DOI:https://doi.org/10.1517/13543784.2014.844788
PubMed ID:24151958

Download

Download PDF  'Antigen-specific tolerization approaches in multiple sclerosis'.
Preview
Content: Accepted Version
Filetype: PDF
Size: 878kB
View at publisher